Preventive chemotherapy and the fight against neglected tropical diseases

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 2, 2012, Pages 237-242

  Montresor, Antonio ^a   Gabrielli, Albis Francesco ^a   Chitsulo, Lester ^a   Ichimori, Kazuyo ^a   Mariotti, Silvio ^a   Engels, Dirk ^a   Savioli, Lorenzo ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

lymphatic filariasis; onchocerciasis; preventive chemotherapy; schistosomiasis; soil transmitted helminthiasis; trachoma

Indexed keywords

ALBENDAZOLE; ANTHELMINTIC AGENT; AZITHROMYCIN; DIETHYLCARBAMAZINE; IVERMECTIN; MEBENDAZOLE; PRAZIQUANTEL;

ANTIBIOTIC THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ENDEMIC DISEASE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE DISTRIBUTION; HEALTH CARE NEED; HELMINTHIASIS; HUMAN; IMMUNIZATION; INFECTION CONTROL; INFECTION PREVENTION; LYMPHATIC FILARIASIS; ONCHOCERCIASIS; PREVENTIVE MEDICINE; REVIEW; SCHISTOSOMIASIS; TRACHOMA; TROPICAL DISEASE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTHELMINTICS; ANTI-BACTERIAL AGENTS; CHEMOPREVENTION; HELMINTHIASIS; HUMANS; INTESTINAL DISEASES, PARASITIC; NEGLECTED DISEASES; PUBLIC HEALTH; SOIL; TRACHOMA; TROPICAL MEDICINE;

EID: 84857563125     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.165     Document Type: Review

References (76)

1. DeFrances CJ, Cullen KA, Kozak LJ. National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data. Vital Health Stat. 13 165, 1-209 (2007).
2. Brun-Buisson C, Doyon F, Carlet J et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: a multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 274(12), 968-974 (1995).
3. Solomkin JS, Mazuski JE, Bradley JS et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection society and the infectious diseases society of America. Clin. Infect. Dis. 50(2), 133-164 (2010).
4. Marshall JC. Principles of source control in the early management of sepsis. Curr. Infect. Dis. Rep. 12(5), 345-353 (2010).
5. Watkins RR, Lemonovich TL. The role for inflammatory markers in the diagnosis and management of infective endocarditis. Infect Dis Clin Pract. 18(2), 87-90 (2010).
6. Aabenhus R, Jensen JUS. Procalcitonin-guided antibiotic treatment of respiratory tract infections in a primary care setting: are we there yet? Prim. Care Respir. J. 20(4), 360-367 (2011).
7. O'Grady NP, Barie PS, Bartlett JG et al. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit. Care Med. 36(4), 1330-1349 (2008).
8. Snider RH Jr, Nylen ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J. Investig. Med. 45(9), 552-560 (1997).
9. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341(8844), 515-518 (1993).
10. Dahaba AA, Metzler H. Procalcitonin's role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator. Minerva Anestesiologica 75(7-8), 447-452 (2009).
11. Charles PE, Ladoire S, Aho S et al. Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram-negative or Gram-positive bacteria. BMC Infect. Dis. 8, 38 (2008).
12. Maruna P, Frasko R, Gurlich R. Plasma procalcitonin in patients with ileus. Relations to other inflammatory parameters. Physiol. Res. 57(3), 481-486 (2008).
13. Reinhart K, Karzai W, Meisner M. Procalcitonin as a systemic inflammatory response to infection. Intensive Care Med. 26(9), 1193-1200 (2000).
14. Lindberg M, Hole A, Johnsen H et al. Reference intervals for procalcitonin and C-reactive protein after major abdominal surgery. Scand. J. Clin. Lab. Invest. 62(3), 189-194 (2002).
15. Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. J. Antimicrob. Chemother. 66(Suppl. 2), ii33-ii40 (2011).
16. Opatrna S, Klaboch J, Opatrny K Jr et al. Procalcitionin levels in peritoneal dialysis patients. Perit. Dial. Int. 25(5), 470-472 (2005).
17. Perren A, Cerutti B, Lepori M et al. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia. Infection 36(2), 163-166 (2008).
18. Gilbert DN. Use of procalcitonin levels as an adjunct to clinical microbiology. J. Clin. Microbiol. 48(7), 2325-2329 (2010).
19. Jones AE, Fiechtl JF, Brown MD, Ballew JJ, Kline JA. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann. Emerg. Med. 50(1), 34-41 (2007).
20. Riedel S, Melendez JH, An AT, Rosenbaum JE, Zenilman JM. Procalcitonin as a marker for the detection of bacteremia and sepsis in the emergency department. Am. J. Clin. Pathol. 135(2), 182-189 (2011).
21. Ivancevic N Radenkovic D, Bumbasirevic V et al. Procalcitonin in preoperative diagnosis of abdominal sepsis. Langenbecks Arch. Surg. 393(3), 397-403 (2008).
22. Harbarth S, Holeckova K, Froidevaux C et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am. J. Respir. Crit. Care. Med. 164(3), 396-402 (2001).
23. Schwarz A, Bolke E, Peiper M et al. Inflammatory peritoneal reaction after perforated appendicitis: continuous peritoneal lavage versus nonlavage. Eur. J. Med. Res. 12(5), 200-205 (2007).
24. Kisacik B, Kalyoncu U, Erol MF et al. Accurate diagnosis of acute abdomen in FMF and acute appendicitis patients: how can we use procalcitonin? Clin. Rheumatol. 26(12), 2059-2062 (2007).
25. Sand M, Trullen XV, Bechara FG et al. A prospective bicenter study investigating the diagnostic value of procalcitonin in patients with acute appendicitis. Eur. Surg. Res. 43(3), 291-297 (2009).
26. Kwan KY, Nager AL. Diagnosing pediatric appendicitis: usefulness of laboratory markers. Am. J. Emerg. Med. 28(9), 1009-1015 (2010).
27. Chakhunashvili L, Inasaridze A, Svanidze S, Samkharadze J, Chkhaidze I. Procalcitonin as the biomarker of inflammation in the diagnostics of pediatric appendicular peritonitis and for the prognosis of early postoperative complications. Georgian Med. News 129, 78-81 (2005).
28. Kafetzis DA, Velissariou M, Nikolaides P et al. Procalcitonin as a predictor of severe appendicitis in children. Eur. J. Clin. Microbiol. Infect. Dis. 24(7), 484-487 (2005).
29. Blab E, Kohlhuber U, Tillawi S et al. Advancements in the diagnosis of acute appendicitis in children and adolescents. Eur. J. Pediatr. Surg. 14(6), 404-409 (2004).
30. Mofidi R, Suttie SA, Patil PV, Ogston S, Parks RW. The value of procalcitonin at predicting the severity of acute pancreatitis and development of infected pancreatic necrosis: systemic review. Surgery 146(1), 72-81 (2009).
31. Rau BM, Kemppainen EA, Gumbs AA et al. Early assessment of pancreatic infections and overall prognosis in severe acute pancreatitis by procalcitonin (PCT). Ann. Surg. 245(5), 745-754 (2007).
32. Riche FC, Cholley BP, Laisne MJ et al. Inflammatory cytokines, C reactive protein, and procalcitonin as early predictors of necrosis infection in acute necrotizing pancreatitis. Surgery 133(3), 257-262 (2003).
33. Kuse ER, Langefeld I, Jaeger K, Kulpmann WR. Procalcitonin in fever of unknown origin after liver transplantation: a variable to differentiate acute rejection from infection. Crit. Care. Med. 28(2), 555-559 (2000).
34. Soliman T, Hetz H, Burghuber C et al. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl. 13(7), 1039-1044 (2007).
35. Schmitt TM, Phillips M, Sawyer RG et al. Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation. Dig. Dis. Sci. 55(11), 3224-3334 (2010).
36. Zazula R, Prucha M, Tyll T, Kieslichova E. Induction of procalcitonin in liver transplant patients treated with anti-thymocyte globulin. Crit. Care 11(6), R131 (2007).
37. Perrakis A, Yedibela S, Schellerer V, Hohenberger W, Muller V. Procalcitonin in the setting of complicated postoperative course after liver transplantation. Transplant. Proc. 42(10), 4187-4190 (2010).
38. van den Broek MA, Olde Damink SW, Winkens B et al. Procalcitonin as a prognostic marker for infectious complications in liver transplant recipients in an intensive care unit. Liver Transpl. 16(3), 402-410 (2010).
39. Spahr L, Morand I, Hadengue A, Vadas L, Pugin J. Procalcitonin is not an accurate marker of spontaneous bacterial peritonitis in patients with cirrhosis. Hepatogastroenterology 48(38), 502-505 (2001).
40. Viallon A, Zeni F, Pouzet V et al. Serum and ascetic procalcitonin levels in cirrhotic patients with spontaneous bacterial peritonitis: diagnostic value and relationship to pro-inflammatory cytokines. Intensive Care Med. 26(8), 1082-1088 (2000).
41. Rau BM, Frigerio I, Buchler MW et al. Evaluation of procalcitonin for predicting septic multiorgan failure and overall prognosis in secondary peritonitis. Arch. Surg. 142(2), 134-142 (2007).
42. Reith HB, Mittelkotter U, Wagner R, Thiede A. Procalcitonin (PCT) in patients with abdominal sepsis. Intensive Care Med. 26(Suppl. 2), S165-S169 (2000).
43. Svoboda P, Kantorova I, Scheer P, Radvanova J, Radvan M. Can procalcitonin help us in timing of re-intervention in septic patients with multiple trauma or major surgery? Hepatogastroenterology 54(74), 359-363 (2007).
44. Novotny AR, Emmanuel K, Hueser N et al. Procalcitonin ratio indicates successful surgical treatment of abdominal sepsis. Surgery 145(1), 20-26 (2009).
45. Oberhofer D, Rumenjak V, Lazic J, Vicic N. Inflammatory indicators in patients after surgery of the large intestine. Acta Med. Croatica 60(5), 429-433 (2006).
46. Thia KT, Chan ES, Ling KL, Ng WY, Jacob E, Ooi CJ. Role of procalcitonin in infectious gastroenteritis and inflammatory bowel disease. Dig. Dis. Sci. 53(11), 2960-2968 (2008).
47. Hochreiter M, Kohler T, Schweiger AM et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit. Care 13(3), R83 (2009).
48. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients. Am. J. Respir. Crit. Care Med. 177(5), 498-505 (2008).
49. Simon P, Milbrandt EB, Emlet LL. Procalcitonin-guided antibiotics in severe sepsis. Crit. Care 12(6), 309 (2008).
50. Tschailowsky K, Hedwig-Geissing M, Braun GG, Radespiel-Troeger M. Predictive value of procalcitonin, interleukin-6, and C-reactive protein for survival in postoperative patients with severe sepsis. J. Crit. Care 26(1), 54-64 (2011).
51. Chastre J, Wolff M, Fagon JY et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290(19), 2588-2598 (2003).
52. Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit. Care. Med. 39(7), 1792-1799 (2011).
53. Bouadma L, Luyt CE, Tubach F et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomized controlled trial. Lancet 375(9713), 463-474 (2010).
54. Charles PE, Tinel C, Barbar S et al. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and outcome. Crit. Care 13(2), R38 (2009).
55. Olah A, Belagyi T, Issekutz A, Makay R, Zaborszky A. Value of procalcitonin quick test in the differentiation between sterile and infected forms of acute pancreatitis. Hepatogastroenterology 52(61), 243-245 (2005).
56. Gabrielli AF, Montresor A, Chitsulo L, Engels D, Savioli L. Preventive chemotherapy in human helminthiasis: theoretical and operational aspects. Trans. R. Soc. Trop. Med. Hyg. 105(12), 683-693 (2011).
57. WHO. Report of the WHO Informal Consultation on the use of chemotherapy for the control of morbidity due to soil-transmitted nematodes in humans. World Health Organization, Geneva, Switzerland (1996).
58. Hotez PJ, Molyneux DH, Fenwick A et al. Control of neglected tropical diseases. N. Engl. J. Med. 357(10), 1018-1027 (2007).
59. WHO/LSHTM/ITI. Trachoma control. A guide for programme managers. World Health Organization, Geneva, Switzerland (2011).
60. Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet 376(9747), 1175-1185 (2010).
61. Olds GR, King C, Hewlett J et al. Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. J. Infect. Dis. 179(4), 996-1003 (1999).
62. Engels D, Ndoricimpa J, Nahimana S, Gryseels B. Control of Schistosoma mansoni and intestinal helminths: 8 year follow-up of an urban school programme in Bujumbura, Burundi. Acta Trop. 58(2), 127-140 (1994).
63. Awadzi K, Edwards G, Duke BO et al. The co-administration of ivermectin and albendazole -safety, pharmacokinetics and efficacy against Onchocerca volvulus. Ann. Trop. Med. Parasitol. 97(2), 165-178 (2003).
64. Mohammed KA, Haji HJ, Gabrielli AF et al. Triple co-administration of ivermectin, albendazole and praziquantel in Zanzibar: a safety study. PLoS Negl. Trop. Dis. 2(1), e171 (2008).
65. Eigege A, Pede E, Miri E et al. Triple drug administration (TDA), with praziquantel, ivermectin and albendazole, for the prevention of three neglected tropical diseases in Nigeria. Ann. Trop. Med. Parasitol. 102(2), 177-179 (2008).
66. Namwanje H, Kabatereine N, Olsen A. A randomised controlled clinical trial on the safety of co-administration of albendazole, ivermectin and praziquantel in infected schoolchildren in Uganda. Trans. R. Soc. Trop. Med. Hyg. 105(4), 181-188 (2011).
67. Anto F, Asoala V, Anyorigiya T et al. Simultaneous administration of praziquantel, ivermectin and albendazole, in a community in rural northern Ghana endemic for schistosomiasis, onchocerciasis and lymphatic filariasis. Trop. Med. Int. Health 16(9), 1112-1119 (2011).
68. Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases. Lancet 373(9674), 1570-1575 (2009).
69. Clements AC, Deville MA, Ndayishimiye O, Brooker S, Fenwick A. Spatial co-distribution of neglected tropical diseases in the east African great lakes region: revisiting the justification for integrated control. Trop. Med. Int. Health 15(2), 198-207 (2010).
70. Croce D, Porazzi E, Foglia E et al. Cost-effectiveness of a successful schistosomiasis control programme in Cambodia (1995-2006). Acta Trop. 113(3), 279-284 (2010).
71. Keiser J, Duthaler U, Utzinger J. Update on the diagnosis and treatment of food-borne trematode infections. Curr. Opin. Infect. Dis. 23(5), 513-520 (2010).
72. Hu VH, Harding-Esch EM, Burton MJ, Bailey RL, Kadimpeul J, Mabey DC. Epidemiology and control of trachoma: systematic review. Trop. Med. Int. Health 15(6), 673-691 (2010).
73. Linehan M, Hanson C, Weaver A et al. Integrated implementation of programs targeting neglected tropical diseases through preventive chemotherapy: proving the feasibility at national scale. Am. J. Trop. Med. Hyg. 84(1), 5-14 (2011).
74. Sinuon M, Tsuyuoka R, Socheat D et al. Control of Schistosoma mekongi in Cambodia: results of eight years of control activities in the two endemic provinces. Trans. R. Soc. Trop. Med. Hyg. 101(1), 34-39 (2007).
75. WHO. Report of the fifteenth meeting of the WHO alliance for the elimination of blinding trachoma by 2020. World Health Organization, Geneva, Switzerland (2011).
76. WHO. Lymphatic Filariasis, Progress report 2000-2009 and strategic plan 2010-2020. World Health Organization, Geneva, Switzerland (2011).